Fig. 4: Univariate and multivariate analysis of OS in whole cohort and cohort with high-benefit predicted by mPRS. | Blood Cancer Journal

Fig. 4: Univariate and multivariate analysis of OS in whole cohort and cohort with high-benefit predicted by mPRS.

From: Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients

Fig. 4: Univariate and multivariate analysis of OS in whole cohort and cohort with high-benefit predicted by mPRS.

A Univariate and multivariate analysis of overall survival in whole cohort. B Univariate and multivariate analysis of overall survival in patients with a high-benefit predicted by molecular prognostic risk signature (mPRS). AML-pCT AML post-cytotoxic therapy, CG cytogenetic, DAC decitabine, HMA hypomethylating agent, mPRS molecular prognostic risk signature, OS overall survival, PS Performance Status, VEN venetoclax.

Back to article page